Cash flow Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.39 USD | -1.04% | -16.45% | -9.63% |
Jan. 15 | Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM | |
Jan. 15 | Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.6M | -106M | -27.2M | -112M | -263M | |||||
Depreciation & Amortization - CF | 13.7M | 10M | 12.1M | 11.6M | 13.4M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 59.3M | 61.6M | 50.7M | 41.1M | 42.8M | |||||
Depreciation & Amortization, Total | 73M | 71.6M | 62.8M | 52.7M | 56.2M | |||||
(Gain) Loss From Sale Of Asset | -900K | -200K | -162M | - | - | |||||
(Gain) Loss on Sale of Investments - (CF) | - | - | - | - | 1.5M | |||||
Asset Writedown & Restructuring Costs | - | 99.7M | 1.8M | 16.9M | 5.7M | |||||
Stock-Based Compensation (CF) | 33.5M | 29.8M | 36.3M | 38.1M | 40.7M | |||||
Tax Benefit from Stock Options | - | - | - | - | - | |||||
Provision and Write-off of Bad Debts | - | - | - | - | - | |||||
Other Operating Activities, Total | 10.6M | 121M | -13.9M | -500K | 21.3M | |||||
Change In Accounts Receivable | -18.2M | -42.8M | -8.8M | -10.3M | -12.5M | |||||
Change In Inventories | 8M | 4.4M | 1.6M | -2.9M | -1.8M | |||||
Change In Accounts Payable | 1.1M | -2.4M | 9.2M | -3.5M | -3.7M | |||||
Change in Unearned Revenues | -500K | -400K | -26.6M | -5M | -200K | |||||
Change In Income Taxes | -25.1M | -217M | 89.9M | 700K | 700K | |||||
Change in Other Net Operating Assets | -2.4M | -5.6M | 55.1M | -80.5M | 44.5M | |||||
Cash from Operations | 83.7M | -147M | 18.2M | -106M | -111M | |||||
Capital Expenditure | -8.6M | -15.8M | -18M | -45.3M | -63.2M | |||||
Cash Acquisitions | -278M | - | - | -57.2M | - | |||||
Divestitures | - | 21.3M | 379M | - | - | |||||
Sale (Purchase) of Intangible assets | - | - | - | - | -10.1M | |||||
Investment in Marketable and Equity Securities, Total | 700K | 71.8M | -86.7M | 25M | 105M | |||||
Cash from Investing | -286M | 56M | 274M | -77.5M | 31.9M | |||||
Short Term Debt Issued, Total | - | - | - | - | - | |||||
Long-Term Debt Issued, Total | 340M | - | - | - | 80M | |||||
Total Debt Issued | 340M | - | - | - | 80M | |||||
Short Term Debt Repaid, Total | - | - | - | - | - | |||||
Long-Term Debt Repaid, Total | -115M | -8.6M | -226M | - | -40.2M | |||||
Total Debt Repaid | -115M | -8.6M | -226M | - | -40.2M | |||||
Issuance of Common Stock | 8.7M | 3.6M | 91.8M | 6.3M | 6M | |||||
Repurchase of Common Stock | -50M | -7.6M | -11.5M | -10.6M | -8.8M | |||||
Other Financing Activities, Total | -1.4M | -200K | -4.5M | -3.7M | 116M | |||||
Cash from Financing | 182M | -4.2M | -151M | -8M | 153M | |||||
Foreign Exchange Rate Adjustments | 2.7M | 2.2M | -600K | -600K | 600K | |||||
Net Change in Cash | -17.7M | -93.4M | 141M | -192M | 74.5M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 11.6M | 10.4M | 4.4M | - | 1.4M | |||||
Cash Income Tax Paid (Refund) | 6.5M | 3.6M | -85.4M | 1.8M | 1.9M | |||||
Levered Free Cash Flow | 59.74M | 110M | 150M | -116M | -61.42M | |||||
Unlevered Free Cash Flow | 67.24M | 116M | 155M | -114M | -59.61M | |||||
Change In Net Working Capital | 49.1M | -114M | -153M | 81.9M | -3.6M | |||||
Net Debt Issued / Repaid | 225M | -8.6M | -226M | - | 39.8M |